SCHEMBL3824701

SCHEMBL3824701

COc1ccc(NC=C(C(=O)O)C(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.59
HPGD P15428 1/20 0.59
HTT P42858 1/20 0.59
NPC1 O15118 6/20 0.53
RAB9A P51151 6/20 0.53
GAA P10253 2/20 0.53
PKM P14618 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
TGM2 P21980 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 2/20 0.48
TP53 P04637 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPT P10636 2/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
EGFR P00533 1/20 0.45
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7068073 0.86 ALDH1A1 (0.55) ALDH1A1HPGDHTTNPC1RAB9A
SCHEMBL7068076 0.85 DHODH (0.65) ALDH1A1HPGDHTTGAAMEN1
SCHEMBL7256742 0.83 ALDH1A1 (0.73) ALDH1A1HPGDHTTNPC1RAB9A
SCHEMBL7256750 0.83 ALDH1A1 (0.73) ALDH1A1HPGDHTTNPC1RAB9A
SCHEMBL29254491 0.83 ALDH1A1 (0.56) ALDH1A1HPGDHTTNPC1RAB9A
SCHEMBL14970806 0.82 ALDH1A1 (0.57) ALDH1A1HPGDHTTNPC1RAB9A
SCHEMBL63413 0.81 NPC1 (0.56) ALDH1A1HPGDHTTNPC1RAB9A
SCHEMBL3852129 0.81 ALDH1A1 (0.45) ALDH1A1HPGDHTTNPC1RAB9A
SCHEMBL31399062 0.81 HTT (0.48) ALDH1A1HPGDHTTNPC1RAB9A
SCHEMBL545096 0.79 DHODH (0.75) ALDH1A1HPGDHTTGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170267648-A1 SUBSTITUTED URACILS AS CHYMASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-21 US disclosed
US-9751843-B2 Substituted uracils and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-05 US disclosed
US-9695131-B2 Substituted uracils as chymase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-07-04 US disclosed
US-20160297771-A1 SUBSTITUTED URACILS AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-13 US disclosed
US-20160244415-A1 SUBSTITUTED URACILS AS CHYMASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-25 US disclosed
EP-1687276-B1 NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES NOVEXEL (FR) 2009-10-14 EP disclosed
EP-1796466-A4 ANTIBACTERIAL AGENTS GLAXO GROUP LTD (GB) 2009-09-02 EP disclosed
EP-1957460-A1 BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-08-20 EP disclosed
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-28 US disclosed
EP-1796466-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2007-06-20 EP disclosed
WO-2007067444-A1 BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-14 WO disclosed
EP-1687276-A1 NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES NOVEXEL (FR) 2006-08-09 EP disclosed
WO-2006002047-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2006-01-05 WO disclosed
WO-2005049575-A1 NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES NOVEXEL (FR) 2005-06-02 WO disclosed
EP-1177177-B1 SUBSTITUTED 4-OXO-QUINOLINE-3-CARBOXAMIDES: GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORP (US) 2005-02-23 EP disclosed
US-6413956-B1 AGONISTS, ANTAGONISTS OR INVERSE AGONISTS AND LOCALIZATION PROBES FOR GAMMA AMINOBUTYRIC ACID BRAIN RECEPTORS; ANXIETY, DEPRESSION, DOWN SYNDROME, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS AND MEMORY ENHANCEMENT NEUROGEN CORPORATION 2002-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267648-A1 SUBSTITUTED URACILS AS CHYMASE INHIBITORS CMA1, UNG, TYMP ALDH1A1 747/4885HPGD 994/4885HTT 3077/4885
US-20160297771-A1 SUBSTITUTED URACILS AND USE THEREOF UNG, UMPS, TYMP ALDH1A1 150/4885HPGD 537/4885HTT 2057/4885
US-20160244415-A1 SUBSTITUTED URACILS AS CHYMASE INHIBITORS UNG, CMA1, TYMP ALDH1A1 479/4885HPGD 877/4885HTT 3589/4885
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MAP3K20, MAP3K1, MAP3K5 ALDH1A1 4226/4885HPGD 3143/4885HTT 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.